$10M Equity Financing Closes for Polaryx, Funds Phase 2 Trial
PLYX sits 21% above its 52-week low of $2.07.
Summary
Polaryx Therapeutics has closed a $10 million private placement equity financing. This capital infusion directly addresses the "substantial doubt about its ability to continue as a going concern" and the "short cash runway through Q3 2026" highlighted in the company's recent 10-K and 10-Q filings. The financing provides critical funding, extending the company's operational runway and specifically supporting the launch of its Soteria Phase 2 basket trial, significantly mitigating immediate financial risk and advancing a key drug candidate.
At the time of this announcement, PLYX was trading at $2.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $118.8M. The 52-week trading range was $2.07 to $48.91. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.